Radioactive microspheres benefit liver met pts

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 6
Volume 17
Issue 6

CHICAGO-Median overall survival was 13 months among 52 patients who received radioactive microspheres (SIR-Spheres) for colorectal cancer liver metastases after chemotherapy failure. The phase II Italian SITILO study was reported at ASCO 2008 (abstract 4078).

CHICAGO-Median overall survival was 13 months among 52 patients who received radioactive microspheres (SIR-Spheres) for colorectal cancer liver metastases after chemotherapy failure. The phase II Italian SITILO study was reported at ASCO 2008 (abstract 4078).

Clinical benefit was seen in 48% (1 CR, 11 PR, 12 SD). In two patients, liver tumors shrank enough to allow potentially curative surgery to be planned. Among the 24 responders, median survival was 16 months vs 8 months for nonresponders (P = .0006); 40% of responders were alive at 2 years vs none of the nonresponders.

“At a minimum, physicians should consider SIR-Spheres for patients who have liver-only or liver-dominant disease and are failing chemotherapy,” said Prof. Maurizio Cosimelli, of the Regina Elena National Cancer Institute, Rome.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
Related Content